- Home
- NVR vs BNTX Comparison
NVR vs BNTX Comparison
Compare NVR & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVR | BNTX |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 24.8B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NVR | BNTX |
|---|---|---|
| Price | $7,377.45 | $94.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $8,366.67 | $137.40 |
| AVG Volume (30 Days) | 20.8K | ★ 1.6M |
| Earning Date | 01-27-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 456.53 | N/A |
| Revenue | ★ $10,582,633,000.00 | $3,698,814,972.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.18 | ★ N/A |
| Revenue Growth | 2.93 | ★ 3.70 |
| 52 Week Low | $6,562.85 | $81.20 |
| 52 Week High | $8,618.28 | $129.27 |
Technical Indicators
Market Signals| Indicator | NVR | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 44.49 |
| Support Level | $7,266.78 | $91.32 |
| Resistance Level | $7,611.69 | $96.19 |
| Average True Range (ATR) | 141.28 | 2.06 |
| MACD | -17.72 | 0.30 |
| Stochastic Oscillator | 26.84 | 41.78 |
Price Performance
Historical ComparisonAbout NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.